

## **Product datasheet for TL314770V**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## Annexin IV (ANXA4) Human shRNA Lentiviral Particle (Locus ID 307)

**Product data:** 

**Product Type:** shRNA Lentiviral Particles

Product Name: Annexin IV (ANXA4) Human shRNA Lentiviral Particle (Locus ID 307)

Locus ID: 307

Synonyms: ANX4; HEL-S-274; P32.5; PAP-II; PIG28; PP4-X; ZAP36

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** ANXA4 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001153, NM 001320698, NM 001320700, NM 001320702, NM 001153.1, NM 001153.2,

NM 001153.3, NM 001153.4, BC011659, BC011659.1, BC000182, BC063672, NM 001365496,

NM 001153.5

UniProt ID: P09525

Summary: Annexin IV (ANX4) belongs to the annexin family of calcium-dependent phospholipid binding

proteins. Although their functions are still not clearly defined, several members of the annexin family have been implicated in membrane-related events along exocytotic and endocytotic pathways. ANX4 has 45 to 59% identity with other members of its family and shares a similar size and exon-intron organization. Isolated from human placenta, ANX4 encodes a protein that has possible interactions with ATP, and has in vitro anticoagulant activity and also inhibits phospholipase A2 activity. ANX4 is almost exclusively expressed in epithelial cells. Several transcript variants encoding different isoforms have been found for

this gene. [provided by RefSeq, Mar 2016]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).